Achieve Life Sciences, Inc. (ACHV)
$
3.58
+0.24 (6.70%)
Key metrics
Financial statements
Free cash flow per share
-1.0255
Market cap
124.2 Million
Price to sales ratio
0
Debt to equity
0.9690
Current ratio
3.5063
Income quality
0.7706
Average inventory
0
ROE
-1.7611
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company that focuses on the development and commercialization of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The operating income ratio is 0.00 indicating the company's operational profitability margin. The gross profit ratio is 0.00 reflecting the efficiency of the company's production and sales operations. However, the company reported a net loss of -$39,827,000.00 indicating challenges in its operations. The operating expenses amount to $39,069,000.00 encompassing various operational costs incurred. On a positive note, the gross profit stands at $0.00 highlighting the company's profitability from core operations. This demonstrates the potential of cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to reduce the severity of nicotine withdrawal symptoms, further solidifying the company's position within the pharmaceutical field. Based in Vancouver, Canada, Achieve Life Sciences has also secured license agreements with Sopharma AD and the University of Bristol, enhancing its collaborative efforts in advancing treatment options. In terms of investment potential, the stock is affordable at $3.34 making it suitable for budget-conscious investors. Notably, the stock has a low average trading volume of 204,877.00 indicating lower market activity, which may appeal to certain investment strategies. With a market capitalization of $124,172,658.00 the company is classified as a small-cap player, which often offers growth opportunities in the early stages of development. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth. This strategic positioning presents a unique opportunity for investors who are looking to support groundbreaking advancements in smoking cessation and nicotine addiction solutions.
Is Achieve Life Sciences, Inc. (ACHV) a good investment?
Investing in Achieve Life Sciences, Inc. (ACHV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Achieve Life Sciences, Inc. (ACHV)'s stock forecast?
Analysts predict Achieve Life Sciences, Inc. stock to fluctuate between $1.84 (low) and $5.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Achieve Life Sciences, Inc.'s market capitalization?
As of 2025-05-30, Achieve Life Sciences, Inc.'s market cap is $124,172,658, based on 34,685,100 outstanding shares.
How does Achieve Life Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Achieve Life Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Achieve Life Sciences, Inc. (ACHV) stock?
To buy Achieve Life Sciences, Inc. (ACHV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACHV. Place an order (Market, Limit, etc.).
What is the best time to invest in Achieve Life Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Achieve Life Sciences, Inc. stock ever split?
Achieve Life Sciences, Inc.'s last stock split was 1:20 on 2020-07-31.
How did Achieve Life Sciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.24 | Growth: -17.33%.
Where can I find Achieve Life Sciences, Inc.'s investor relations reports?
Visit https://www.achievelifesciences.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Achieve Life Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Achieve Life Sciences, Inc. stock?
All-time high: $16.10 (2021-02-16) | All-time low: $1.84 (2025-04-09).
What are the key trends affecting Achieve Life Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. “The Achieve team is fully committed to finalizing the NDA for submission to the FDA next month.
globenewswire.com
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT.
globenewswire.com
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo
seekingalpha.com
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets Francois Brisebois - Oppenheimer and Company Justin Walsh - Jones Trading Brandon Folkes - Rodman & Renshaw John Vandermosten - Zacks SCR Boris Tolkachev - Freedom Broker Operator Greetings, and welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2024 Earnings Call and Webcast. At this time all participants are in a listen-only mode.
globenewswire.com
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Highlights Reached key milestones in the ORCA-OL long-term exposure trial, including completion of enrollment and meeting the requirement of 300 participants receiving six months of cumulative cytisinicline treatment, as required for the submission of the NDA Announced positive outcomes from two data safety monitoring committee (DSMC) reviews with no safety concerns in the ORCA-OL clinical trial Appointed Dr. Kristen Slaoui and Nancy Phelan to the Board of Directors, bringing extensive leadership experience in corporate strategy and commercialization Appointed Mark Oki as Chief Financial Officer to oversee the company's financial strategy and operational initiatives Announced the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for defining cytisinicline development as a treatment for vaping cessation “We are thrilled with our progress to date and excited to have the NDA submission on track for the end of next quarter, furthering our mission to bring cytisinicline to market as the first new FDA-approved nicotine dependence treatment in nearly 20 years,” said Rick Stewart, Achieve's Chief Executive Officer.
globenewswire.com
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide an update on the cytisinicline development program on Tuesday, March 11, 2025, at 8:30 AM EDT.
See all news
